|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 原发灶切除+化疗与单独化疗治疗存在无症状、同时性、不可切除转移灶的结直肠癌患者的疗效对比--一项随机临床试验(JCOG1007;iPACS)显示文摘目的:关于在原发灶切除术(primary tumor resection,PTR)后进行化疗能否改善存在无症状的原发灶及同时性、不可切除转移灶的结直肠癌患者的生存情况,目前仍有争议。方法:本试验为关于PTR后进行化疗对比单独化疗治疗结直肠癌患者总生存(overall survival,OS)情况的Ⅲ期随机研究,入组患者(Ⅳ期)存在无症状的不可切除的转移灶,转移灶位于肝、肺、远处淋巴结或腹膜,数量为3个及以下。所采用的化疗方案在入组前已决定,包括mFOLFOX6+贝伐珠单抗或者CapeOX+贝伐珠单抗。主要研究终点是意向治疗人群的OS。 | 俞少俊 KANEMITSU Y SHITARA K MIZUSAWA J | 2021 | 结直肠肛门外科2021，27，2： | 12 |
| 2 | HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer显示文摘BACKGROUND The clinical significance of intratumoral human epidermal growth factor receptor 2(HER2)heterogeneity is unclear for HER2-positive gastric cancer,although it has been reported to be a significant prognosticator for HER2-positive breast cancer,which has received trastuzumab-based chemotherapy.AIM To clarify the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer,which has received trastuzumab-based chemotherapy.METHODS Patients with HER2-positive unresectable or metastatic gastric cancer who received trastuzumab-based chemotherapy as a first line treatment were included.The patients were classified into two groups according to their intratumoral HER2 heterogeneity status examined by immunohistochemistry(IHC)on endoscopic biopsy specimens before treatment,and their clinical response to chemotherapy and survival were compared.RESULTS A total of 88 patients were included in this study,and HER2 heterogeneity was observed in 23(26%)patients(Hetero group).The overall response rate was significantly better in patients without HER2 heterogeneity(Homo group)(Homo vs Hetero:79.5%vs 35.7%,P=0.002).Progression-free survival of trastuzumab-based chemotherapy was significantly better in the Homo group(median,7.9 vs 2.5 mo,HR:1.905,95%CI:1.109-3.268).Overall survival was also significantly better in the Homo group(median survival time,25.7 vs 12.5 mo,HR:2.430,95%CI:1.389-4.273).Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors(HR:3.115,95%CI:1.610-6.024).CONCLUSION IHC of HER2 heterogeneity is the pivotal predictor for trastuzumab-based chemotherapy.Thus,HER2 heterogeneity should be considered during the assessment of HER2 expression. | Akio Kaito Takeshi Kuwata Masanori Tokunaga Kohei Shitara Reo Sato Tetsuo Akimoto Takahiro Kinoshita | 2019 | World Journal of Clinical Cases2019，7，15： | 5 |
| 3 | Phammcokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A ( HMG-CoA ) reduc- tase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions 显示文摘 | Shitara Y Sugiyanla Y | 2006 | Pharmacol Ther2006，112，1： | 1 |
| 4 | Increased FGFRI copy number in lung sqnamous cell carcinomas显示文摘 | Sasaki H Shitara M Yokota K | 2012 | Mol Med Rep2012，5，3： | 1 |
| 5 | Cycleave polymerase chain reaction method is practically ap- plicable for V- Ki -ras2 Kirsten rat sarcoma viral oncogene homo- log (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer 显示文摘 | Yokota T Shibata N Ura T Takahari D Shitara K Muro K | 2010 | Transl Res2010，，： | 1 |
| 6 | Association of fluoropyrimidines, platinumagents, taxanes, and irinotecan in any line ofchemotherapy with survival in patients withadvanced gastric cancer显示文摘 | SHITARA K MATSUO K MIZOTA A | 2011 | Gastric Cancer2011，14，2： | 1 |
| 7 | Clinical significance of or- ganic anion transporting polypeptides (OATPs) in drug disposi- tion: their roles in hepatic clearance and intestinal absorption 显示文摘 | Shitara Y Maeda K Ikejiri K | 2013 | Biopharm Drug Dispos2013，34，1： | 1 |
| 8 | Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment显示文摘 | Shitara K Yatabe Y Matsuo K Sugano M Kondo C Takahari D | 2013 | Gastric Cancer2013，16，： | 1 |
| 9 | Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy显示文摘 | Nomura M Shitara K Kodaira T | 2012 | Int J Radiat Oncol Biol Phys2012，82，2： | 1 |
| 10 | The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling显示文摘 | Kato M Shitara Y Sato H | 2008 | Pharm Res2008，25，8： | 1 |
| 11 | Mutation analysis of transforming growth factor beta type Ⅱ receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma显示文摘 | Osawa H Shitara Y Shoji H | 2000 | Int J Oncol2000，17，4： | 1 |
| 12 | Maternal inheritance of mouse mtDNA in interspecific hybrids: segregation of the leaked paternal mtDNA followed by the prevention of subsequent paternal leakage显示文摘 | SHITARA H HAYASHI J I TAKAHAMA S | 1998 | Genetics1998，148，2： | 1 |
| 13 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines 显示文摘 | Shitara K Yuki S Yoshida M | 2012 | Invest New Drugs2012，30，2： | 1 |
| 14 | The quantitative prediction of CYP- mediated drug interaction by physiologically based pharmacokinetic modeling 显示文摘 | Kato M Shitara Y Sato H Yoshisue K Hirano M Ikeda T | 2008 | Pharm Res2008，25，8： | 1 |
| 15 | Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma 显示文摘 | Miyazaki T Karo H Shitara Y | 2000 | Cancer2000，89，5： | 1 |
| 16 | Polymorphisms in intron 1 ofthe EGFR gene in non-small cell lung cancer patients 显示文摘 | Shitara M Sasaki H Yokota K | 2012 | Exp TherMed2012，4，5： | 1 |
| 17 | DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients 显示文摘 | Sasaki H Shitara M Yokota K | 2012 | Oncol Lett2012，4，1： | 1 |
| 18 | Role of VM-26 on glioma cells in vitro, analysis of gocells and rectraiment显示文摘 | Yamamoto H Shitara N Nomura K | 1978 | Neurol Med Chirl1978，18，6： | 1 |
| 19 | Opposite effects of the overexpression of protein kinase C γ and δ on the growth properties of human glioma cell line U251 MG显示文摘 | Mishima K Ohno S Shitara N | 1994 | Biochem Biophs Res Commun1994，201，1： | 1 |
| 20 | Prognosis of recurrent non?small cell lung cancer following completeresection显示文摘 | Hidefumi Sasaki Ayumi Suzuki Tsutomu Tatematsu Masayuki Shitara Yu Hikosaka Katsuhiro Okuda Satoru Moriyama Motoki Yano Yoshitaka Fujii | 2014 | Oncology Letters2014，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员